Appetite Suppression Drug
Obesity from overfeeding is common in companion animals and is best accomplished by teaching the owner and regulating the animal’s diet.
The U.S. Food and Drug Administration (FDA) approved the diet drug dirlotapide (Slentrol, Pfizer In York, NY) for dogs on January 5, 2007. Dirlotapide is the first FDA-approved product in a new class of drugs called selective microsomal triglyceride transfer protein (MTP) inhibitors . These types of agents block the assembly and release of lipoproteins into the bloodstream.
The initial dosage of 0.5 mg/kg is doubled after 14 days and then adjusted monthly; the maximum permitted daily dosage is 1 mg/kg, although dosages as high as 10 mg/kg have been administered to dogs without severe adverse effects in safety studies. Dirlotapide can be used without changing the dog’s current feeding or exercise regimens, but food intake should be monitored during weight stabilization to establish feeding and exercise routines that will minimize weight gain after treatment. Anorexia, emesis, and loose feces occur in some dogs. The incidence of emesis generally increases with dose and decreases with treatment time. Increases in hepatic transaminase activity were seen in dogs treated with >1.5 mg/kg/day but were not associated with clinical signs or histopathologic evidence of hepatic degeneration or necrosis.
Dirlotapide should not be used in cats. It increases the risk of hepatic lipidosis during weight loss in obese cats. Dirlotapide is not recommended for use in dogs currently receiving long-term glucocorticoid therapy or in dogs with liver disease. In people, adverse reactions associated with ingesting dirlotapide include abdominal distention, abdominal pain, diarrhea, flatulence, headache, increased serum transaminases, nausea, and vomiting.( Merck Veterinary Manual)